<DOC>
	<DOCNO>NCT01300988</DOCNO>
	<brief_summary>The investigator ' vitro data suggest Neurokinin-1 receptor antagonist like aprepitant decrease expression CCR5 , essential co-receptor life cycle HIV , surface macrophage lymphocytes level least similar observe patient heterozygous CCR5 32 mutation . Together direct potential antiviral effect could alter disease progression patient HIV infection . The investigator ' hypothesis aprepitant safe , tolerable antiviral activity HIV infect individual . This randomized , placebo control , double blind study determine safety antiviral activity aprepitant comparing change HIV RNA viral load 2 week aprepitant monotherapy . 18 HIV infect male female ≥ 18 year old early infection CD4 cell count ≥ 350 cells/mm3 . Subjects randomize 1:1 receive 375 mg aprepitant ( Emend® ) placebo .</brief_summary>
	<brief_title>Effects Treatment With Aprepitant ( Emend® ) HIV Infected Individuals . 375 mg Dose</brief_title>
	<detailed_description>DESIGN Randomized , placebo control , double blind study determine safety antiviral activity aprepitant comparing change HIV RNA viral load 2 week aprepitant monotherapy . DURATION 42 day . SAMPLE SIZE POPULATION 18 HIV infect male female ≥ 18 year old early infection CD4 cell count ≥ 350 cells/mm3 . REGIMEN Subjects randomize 1:1 receive aprepitant ( Emend® ) placebo . Arm A : Aprepitant placebo Arm B : Aprepitant 375 mg QD HYPOTHESIS AND STUDY OBJECTIVES Hypothesis : Aprepitant safe , tolerable , antiviral activity HIV infect individual . Primary Objectives : To assess safety tolerability 375 mg aprepitant 2 week To assess response plasma HIV-1 RNA 375 mg aprepitant compare baseline . Secondary Objectives : To investigate course duration antiretroviral response 375 mg aprepitant give 14-day period . To evaluate dose-response pharmacokinetic pharmacodynamic relationship viral RNA change aprepitant plasma level . To evaluate aprepitant effect CD4+ CD8+ T-cell count , circulate SP level , natural killer cell number function CCR5 expression peripheral PBMCs . To evaluate effect aprepitant viral tropism envelope sequence main HIV-1 population participant . To assess viral drug susceptibility conjunction baseline coreceptor tropism phenotype change coreceptor phenotype exposure aprepitant . To evaluate aprepitant effect fast plasma glucose , insulin , HDL , free fatty acid , triglyceride concentration 14 day treatment . To provide preliminary description change baseline sleep quality , anxious mood , depress mood neurocognitive measure 2 week aprepitant therapy .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Neurokinin-1 Receptor Antagonists</mesh_term>
	<criteria>HIV1 infection , document rapid HIV test FDAApproved HIV1 Enzyme Chemiluminescence Immunoassay ( E/CIA ) test kit confirm Western blot time prior study entry . CD4+ cell count &gt; = 350/mm3 obtain within 90 day prior study entry Plasma HIV1 RNA &gt; =2,000 copies/mL measure standard assay perform within 90 day prior study entry . CCR5 tropic virus exclusively determine Monogram tropism assay ( PhenoSense Entry™ ) perform within 90 day study entry . Laboratory value obtain within 30 day prior study entry , follow : Absolute neutrophil count ( ANC ) &gt; = 750/mm3 Hemoglobin &gt; = 10.0 g/dL Platelet count &gt; = 100,000/mm3 Creatinine &lt; = 2 x ULN AST ( SGOT ) , ALT ( SGPT ) , alkaline phosphatase &lt; = 2 x ULN Total bilirubin &lt; = 2.5 x ULN Albumin &gt; = 3 g/dL Female subject reproductive potential must negative spot urine pregnancy test result ( sensitivity least 50 mIU/mL ) perform entry , prior start initial study treatment . All subject must agree participate conception process study drug 30 day stop medication . Karnofsky performance score &gt; = 80 within 30 day prior study entry . Men woman &gt; 18 year age . Ability willingness subject give write informed consent . Willing return followup visit day 42 . Subjects take precautionary concomitant medication must stable dos &gt; 8 week prior study entry plan change medication dos duration study . Receipt antiretroviral treatment within 16 week prior study entry intent initiate antiretroviral therapy within 60 day entry . Diabetes require treatment oral hypoglycemics insulin therapy . Pregnancy within 90 day prior study entry . Breastfeeding . Use drug inhibitor inducer metabolism cytochrome P450 CYP3A4 CYP2C9 ( warfarin phenytoin ) within 7 day study entry . Use systemic corticosteroid hormonal agent within 90 day prior study entry . Use immunomodulator , HIV vaccine , investigational therapy within 90 day prior study entry . Any vaccination within 30 day prior study entry . Use systemic cytotoxic chemotherapy within 90 day prior study entry . History allergy aprepitant formulation . Active drug alcohol use dependence , opinion investigator , would interfere adherence study requirement . History chronic active hepatitis B C infection severe hepatic dysfunction ( ChildPugh score &gt; 9 ) regardless etiology Serious illness require systemic treatment and/or hospitalization subject either complete therapy clinically stable therapy , opinion investigator , least 14 day prior study entry . Weight &lt; 40 kg 88 lb . within 90 day prior study entry . History severe psychiatric comorbidities , depression , schizophrenia , mania , psychosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>Neurokinin-1 receptor antagonist</keyword>
	<keyword>CCR5 expression</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>